Product profile · United States
APREPITANT
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
Post-anchor patent or partial-scope exclusivity risk retained for Deep Review.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| US5719147 | 2015-04-17 | HISTORICAL_REFERENCE_NOT_EXACT_OB U-853 | Y | N | TRUE_DS Morpholine antagonist substance claims cover aprepitant. Historical FDA date 2015-04-17 was checked against PTE records. The substance basis is reused across oral and IV formulations. | — | — | — |
| 12115254 | 2035-09-18 | HISTORICAL_REFERENCE_NOT_EXACT_OB — | N | N | DP / FORMULATION_DEPENDENT_U Later formulation claims broaden emulsifier concentration or emulsifier:aprepitant ratio. The target FDA label specifies lecithin 3240 mg, aprepitant 130 mg (24.923:1), and soybean oil 1735.2 mg. This is distinguished from narrower 14 wt% or 18:1-22:1 claims and retained as a Deep Review risk. Actual pH, satisfaction of every claim element and infringement are not asserted. | — | — | — |
| 12115255 | 2035-09-18 | HISTORICAL_REFERENCE_NOT_EXACT_OB — | N | N | DP / FORMULATION_DEPENDENT_U Later formulation claims broaden emulsifier concentration or emulsifier:aprepitant ratio. The target FDA label specifies lecithin 3240 mg, aprepitant 130 mg (24.923:1), and soybean oil 1735.2 mg. This is distinguished from narrower 14 wt% or 18:1-22:1 claims and retained as a Deep Review risk. Actual pH, satisfaction of every claim element and infringement are not asserted. | — | — | — |
| 12290520 | 2035-09-18 | HISTORICAL_REFERENCE_NOT_EXACT_OB — | N | N | DP / FORMULATION_DEPENDENT_U Later formulation claims broaden emulsifier concentration or emulsifier:aprepitant ratio. The target FDA label specifies lecithin 3240 mg, aprepitant 130 mg (24.923:1), and soybean oil 1735.2 mg. This is distinguished from narrower 14 wt% or 18:1-22:1 claims and retained as a Deep Review risk. Actual pH, satisfaction of every claim element and infringement are not asserted. | — | — | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| NCE | 2003-03-26 | 2008-03-26 | Historical protection covering the active ingredient. This is a reference period, not a new grant to the later NDA. | Y | Y | 2008-03-26 | — | Source |
2026-10-13 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED
2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| No generic approval facts are linked to this product. | |||||||
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 0 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No final-approval records are linked to this product. | ||||||
Decision evidence (6)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| PATENT | 2015-04-17 | CANONICAL_ANCHOR | Morpholine antagonist substance claims cover aprepitant. Historical FDA date 2015-04-17 was checked against PTE records. The substance basis is reused across oral and IV formulations. | Source |
| PATENT | 2035-09-18 | FTO_TAIL | Later formulation claims broaden emulsifier concentration or emulsifier:aprepitant ratio. The target FDA label specifies lecithin 3240 mg, aprepitant 130 mg (24.923:1), and soybean oil 1735.2 mg. This is distinguished from narrower 14 wt% or 18:1-22:1 claims and retained as a Deep Review risk. Actual pH, satisfaction of every claim element and infringement are not asserted. | Source |
| PATENT | 2035-09-18 | FTO_TAIL | Later formulation claims broaden emulsifier concentration or emulsifier:aprepitant ratio. The target FDA label specifies lecithin 3240 mg, aprepitant 130 mg (24.923:1), and soybean oil 1735.2 mg. This is distinguished from narrower 14 wt% or 18:1-22:1 claims and retained as a Deep Review risk. Actual pH, satisfaction of every claim element and infringement are not asserted. | Source |
| PATENT | 2035-09-18 | FTO_TAIL | Later formulation claims broaden emulsifier concentration or emulsifier:aprepitant ratio. The target FDA label specifies lecithin 3240 mg, aprepitant 130 mg (24.923:1), and soybean oil 1735.2 mg. This is distinguished from narrower 14 wt% or 18:1-22:1 claims and retained as a Deep Review risk. Actual pH, satisfaction of every claim element and infringement are not asserted. | Source |
| REGULATORY_EXCLUSIVITY | 2008-03-26 | CANONICAL_ANCHOR | Historical protection covering the active ingredient. This is a reference period, not a new grant to the later NDA. | Source |
| REGULATORY_STATUS | 2015-04-17 | CANONICAL_DECISION | Post-anchor patent or partial-scope exclusivity risk retained for Deep Review. | Source |
Independent legal-event information
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.